Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerhed og effekt af Ellacor® Micro-coring® ved anvendelse af bedste praksis for teknik og eftersundhed

12. november 2026 opdateret af: Cytrellis Biosystems, Inc.

Sikkerhed og effekt af Ellacor mikro-koring efter bedste praksis for teknik og efterbehandling

Since its inception of being marketed in the United States in 2021, physicians have used various post procedure skin care regimen to facilitate recovery. This study aims to examine the use of three post care products in five skin care regimens

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Florida
      • Miami, Florida, Forenede Stater, 33173
        • Miami Dermatology And Laser Institute
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 42022
        • Caloaesthetics Plastic Surgery Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

45 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male and female adult, between the ages of 45 and 65
  2. Fitzpatrick Skin Type I to IV
  3. Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5.
  4. Willingness to sign Informed Consent Form

Exclusion Criteria:

  1. Pregnant women or nursing mothers
  2. Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
  3. Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
  4. Patients with a history or presence of any clinically significant bleeding disorder

i. Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus e. Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection) f. Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days g. Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area h. Patients have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old i. Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months j. Patients with scars less than six (6) months old in the treatment area k. During the study time frame, unwilling to refrain from receiving these following aesthetic treatments: toxin, filler, any skin resurfacing (laser, RF, ultrasound, microneedling, etc.); l. Have enrolled in another clinical trial during or overlapping part of this study m. Unwilling to have facial photography taken for the study purpose n. Any physical or psychological factors, in the judgment of the study investigator, may prevent subject from performing the procedure correctly.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Regenerating Skin Nectar (by Alastin) + Tegaderm

Alastin to be applied post procedure followed up Tegaderm. Tegaderm will be left on for 12 hours. Alastin will be applied twice daily for the duration of the study

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navne:
  • mikrokoring
  • dermal mikro-korning
  • ellacor
Aktiv komparator: Kerra+ Recovery Cream (by Quthero) + Tegaderm

Patients will receive Kerra+ post procedure followed by Tegaderm. The Tegaderm is removed after 12 hours. Kerra+ will be applied twice daily for the duration of the study.

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navne:
  • mikrokoring
  • dermal mikro-korning
  • ellacor
Aktiv komparator: Ariessence Platelet-Derived Growth Factor (PDGF) solution +Alastin + Tegaderm

Patients will receive PDGF immediately post procedure followed by Alastin followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Alastin will continue to be applied twice daily for the duration of the study

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navne:
  • mikrokoring
  • dermal mikro-korning
  • ellacor
Aktiv komparator: Ariessence PDGF solution + Kerra+ Recovery Cream + Tegaderm

Patients will receive PDGF immediately post procedure followed by Kerra+ followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Kerra+ will continue to be applied twice daily for the duration of the study

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navne:
  • mikrokoring
  • dermal mikro-korning
  • ellacor
Aktiv komparator: Tegaderm Only

Patient will only receive Tegaderm for post-care

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navne:
  • mikrokoring
  • dermal mikro-korning
  • ellacor

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Global Aesthetic Improvement Scale (GAIS)
Tidsramme: GAIS Assessment will be performed under a timeframe of 90 days

Treatment improvement will be evaluated based off the 7 grade GAIS by both the subject and the physician.

GAIS Assessment will be performed under a timeframe of 90 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Assessment
Tidsramme: Clinical assessment will be performed at each follow up throughout the study period.

Clinical assessment will be performed, and graded on a 0-3 scale on Day 0, Day 7, Day 30, and Day 90- 0 = absent, 1 = mild, 2 = moderate, 3 = severe for the following side effects:

  • Bleeding
  • Erythema - redness
  • Ecchymosis - bruising
  • Dryness, roughness
  • Crusting Tenderness
  • Numbness
  • Edema - swelling
  • Burning
  • Tightness/Pulling of Skin
  • Pain/Discomfort
  • Tingling
  • Skin Peeling
  • Circular Marks on skin
  • Any other observation
Clinical assessment will be performed at each follow up throughout the study period.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety Outcomes
Tidsramme: Day 0 to end of study period

Safety will be evaluated throughout the duration of the study by recording adverse events on Day 0, Day 7, Day 30, and Day 90

Day 0 to end of study period
Subject Satisfaction Survey
Tidsramme: Day 90

Subject satisfaction data will be collected via a written questionnaire at the 90-day post procedure final follow-up visit. This questionnaire will be composed of 5-point Likert scale questions, as well as free-text responses. Subjects will be asked to determine overall satisfaction with the treatment. The choices will be: 1) very unsatisfied; 2) somewhat unsatisfied; 3) neither unsatisfied nor satisfied; 4) somewhat satisfied; 5) very satisfied.

Day 90

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. november 2025

Primær færdiggørelse (Anslået)

1. marts 2027

Studieafslutning (Anslået)

1. april 2027

Datoer for studieregistrering

Først indsendt

19. november 2025

Først indsendt, der opfyldte QC-kriterier

2. december 2025

Først opslået (Faktiske)

3. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2025

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner